BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 24117733)

  • 1. Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1.
    Luerman GC; Nguyen C; Samaroo H; Loos P; Xi H; Hurtado-Lorenzo A; Needle E; Stephen Noell G; Galatsis P; Dunlop J; Geoghegan KF; Hirst WD
    J Neurochem; 2014 Feb; 128(4):561-76. PubMed ID: 24117733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.
    Lavalley NJ; Slone SR; Ding H; West AB; Yacoubian TA
    Hum Mol Genet; 2016 Jan; 25(1):109-22. PubMed ID: 26546614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?
    Gillardon F
    J Neurochem; 2009 Sep; 110(5):1514-22. PubMed ID: 19545277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
    Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
    Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.
    Gillardon F; Schmid R; Draheim H
    Neuroscience; 2012 Apr; 208():41-8. PubMed ID: 22342962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRRK2 guides the actin cytoskeleton at growth cones together with ARHGEF7 and Tropomyosin 4.
    Häbig K; Gellhaar S; Heim B; Djuric V; Giesert F; Wurst W; Walter C; Hentrich T; Riess O; Bonin M
    Biochim Biophys Acta; 2013 Dec; 1832(12):2352-67. PubMed ID: 24075941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.
    Lin CH; Lin HI; Chen ML; Lai TT; Cao LP; Farrer MJ; Wu RM; Chien CT
    Hum Mol Genet; 2016 May; 25(10):1965-1978. PubMed ID: 26931464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.
    Garcia-Miralles M; Coomaraswamy J; Häbig K; Herzig MC; Funk N; Gillardon F; Maisel M; Jucker M; Gasser T; Galter D; Biskup S
    PLoS One; 2015; 10(4):e0118947. PubMed ID: 25830304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3β.
    Kawakami F; Shimada N; Ohta E; Kagiya G; Kawashima R; Maekawa T; Maruyama H; Ichikawa T
    FEBS J; 2014 Jan; 281(1):3-13. PubMed ID: 24165324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation of p53 by LRRK2 induces microglial tumor necrosis factor α-mediated neurotoxicity.
    Ho DH; Seol W; Eun JH; Son IH
    Biochem Biophys Res Commun; 2017 Jan; 482(4):1088-1094. PubMed ID: 27914807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
    Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
    Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.
    Plowey ED; Cherra SJ; Liu YJ; Chu CT
    J Neurochem; 2008 May; 105(3):1048-56. PubMed ID: 18182054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression.
    Ho DH; Kim H; Kim J; Sim H; Ahn H; Kim J; Seo H; Chung KC; Park BJ; Son I; Seol W
    Mol Brain; 2015 Sep; 8():54. PubMed ID: 26384650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity.
    Zach S; Felk S; Gillardon F
    PLoS One; 2010 Oct; 5(10):e13191. PubMed ID: 20949042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration.
    Caesar M; Zach S; Carlson CB; Brockmann K; Gasser T; Gillardon F
    Neurobiol Dis; 2013 Jun; 54():280-8. PubMed ID: 23318930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain.
    Civiero L; Cirnaru MD; Beilina A; Rodella U; Russo I; Belluzzi E; Lobbestael E; Reyniers L; Hondhamuni G; Lewis PA; Van den Haute C; Baekelandt V; Bandopadhyay R; Bubacco L; Piccoli G; Cookson MR; Taymans JM; Greggio E
    J Neurochem; 2015 Dec; 135(6):1242-56. PubMed ID: 26375402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity.
    Heo HY; Park JM; Kim CH; Han BS; Kim KS; Seol W
    Exp Cell Res; 2010 Feb; 316(4):649-56. PubMed ID: 19769964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity.
    Kalogeropulou AF; Zhao J; Bolliger MF; Memou A; Narasimha S; Molitor TP; Wilson WH; Rideout HJ; Nichols RJ
    Biochem J; 2018 Apr; 475(7):1271-1293. PubMed ID: 29519959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dual inhibitor targeting HMG-CoA reductase and histone deacetylase mitigates neurite degeneration in
    Lin CH; Lin HY; Fang JM; Chen CC
    Aging (Albany NY); 2020 Nov; 12(24):25581-25598. PubMed ID: 33231564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.